drugset / Trial / NCT05058976
Romosozumab Use to Build Skeletal Integrity
Phase 4
Active not recruiting
184 enrolled
Susan L. Greenspan
National Institute on Aging (NIA) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to find out if one year of romosozumab (Evenity®), a monthly injection given in the arm under the skin, prior to an infusion of zoledronic acid Reclast®, works to treat bone loss and prevent it from worsening in older women (ages 65 and older) who have osteoporosis and reside in long-term care (LTC) facilities.
Timeline
- Start
- 2021-09-15
- Primary completion
- 2027-03-31
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Romosozumab | Monoclonal antibody | 210 mg | Subcutaneous |
| Background | Zoledronic acid | Other / unclassified | 5 mg | Intravenous |